Stocks and Investing Stocks and Investing
Mon, March 8, 2021
Fri, March 5, 2021
Thu, March 4, 2021
Wed, March 3, 2021
Tue, March 2, 2021

Joseph Schwartz Maintained (SRPT) at Buy with Increased Target to $126 on, Mar 2nd, 2021


Published on 2024-10-27 15:49:52 - WOPRAI, Joseph Schwartz
  Print publication without navigation


Joseph Schwartz of SVB Leerink, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $125 to $126 on, Mar 2nd, 2021.

Joseph has made no other calls on SRPT in the last 4 months.



There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 5 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Citigroup" Downgraded from Strong Buy to Hold and Held Target at $108 on, Tuesday, January 12th, 2021
  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
  • Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021


These are the ratings of the 4 analyists that currently disagree with Joseph


  • Difei Yang of "Mizuho" Maintained at Strong Buy with Increased Target to $160 on, Friday, February 26th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $135 on, Friday, February 26th, 2021
  • Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
  • Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021